Lumos Diagnostics Raises AU$25m in Oversubscribed Pre-IPO Capital Raise
Retrieved on:
Tuesday, October 6, 2020
Research, Medical devices, Medical Supplies, Infectious diseases, Other Health, Health, General Health, Other Science, Science, Financial markets, Lumos, Stock market, States and territories of Australia, Initial public offering, Australian Securities Exchange, Security, Ellerston, New South Wales, New South Wales
Lumos Diagnostics , a rapid point-of-care diagnostics company, has closed an oversubscribed AU$25 million pre-IPO capital raise, ahead of an anticipated 2021 Australian Securities Exchange (ASX) listing.
Key Points:
- Lumos Diagnostics , a rapid point-of-care diagnostics company, has closed an oversubscribed AU$25 million pre-IPO capital raise, ahead of an anticipated 2021 Australian Securities Exchange (ASX) listing.
- The capital was raised from a combination of institutional funds, including Perennial Value and Ellerston Capital, and sophisticated investors, many of whom have backed Lumos through previous capital raises.
- Lumos has built a strong foundation over the past few years, and this funding will enable us to accelerate our growth plan, said Sam Lanyon, executive chair of Lumos Diagnostics.
- David Keelan, Portfolio Manager at Ellerston Capital and a first-time Lumos investor, said: Im really excited by Lumoss potential.